Once-Daily Cefazolin and Probenecid for Skin and Soft Tissue Infections

Annals of Pharmacotherapy

Volumn 38, Issue 3, 2004, Pages 458-463

  Cox, Victoria C ^a,b   Zed, Peter J ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b LIONS GATE HOSPITAL   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Cefazolin; Cellulitis; Probenecid; Skin and soft tissue infections

Indexed keywords

CEFAZOLIN; CEFTRIAXONE; PLACEBO; PROBENECID;

ANTIBIOTIC THERAPY; BETA HEMOLYTIC STREPTOCOCCUS; CELLULITIS; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EMBASE; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; GINGIVA DISEASE; HEADACHE; HUMAN; LANGUAGE; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; VOMITING;

ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CEFAZOLIN; HALF-LIFE; HUMANS; MALE; PROBENECID; RANDOMIZED CONTROLLED TRIALS; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME; URICOSURIC AGENTS;

EID: 1242271404     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D251     Document Type: Review

References (37)

1. Hook EW, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986;146:295-7.
2. Goldgeier MH. The microbial evaluation of acute cellulitis. Cutis 1983;31:649-56.
3. Sachs MK. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 1990:150:1907-12.
4. Ginsberg MB. Cellulitis: analysis of 101 cases and review of the literature. South Med J 1981;74:530-3.
5. Bradsher RW, Snow RM. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Am J Med 1984;77:63-7.
6. Gordin FM, Wofsy CB, Mills J. Once-daily ceftriaxone for skin and soft tissue infections. Antimicrob Agents Chemother 1985;27:648-9.
7. Scully BE, Fu KP, Neu HC. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection. Am J Med 1984;77:112-7.
8. Goldstein NH, Topiel MS, Ehrlich A, Simon G. A comparative study of ceftriaxone vs cefazolin in the treatment of cellulitis. Curr Ther Res 1984;36:653-7.
9. Slutkin G, Marzouk J, Dall L, Mills J. Comparision of cefonicid and cefazolin for treatment of soft tissue infections. Rev Infect Dis 1984;6(suppl 4):S853-6.
10. Parish LC, Witkowski JA. Ceforanide compared with cefazolin in skin and soft tissue infections. Cutis 1984;33:313-9.
11. Chirurgi VA, Edelstein H, Oster SE, Karp R, Cassano KB, Aiken S, et al. Randomized comparison trial of teicoplanin IV, teicoplanin IM and cefazolin for skin and soft tissue infections caused by gram-positive bacteria. South Med J 1994;87:875-80.
12. Brown G, Chamberlain R, Goulding J, Clarke A. Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. J Emerg Med 1996;14:547-51.
13. Grayson LM, McDonald M, Gibson K, Athan E, Munckhof WJ, Paull P, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infect Dis 2002;34:1440-8.
14. Stevens DL. Teicoplanin for skin and soft tissue infections: an open study and randomized, comparative trial versus cefazolin. J Infect Chemother 1999;5:40-5.
15. Dong SL, Kelly KD, Oland RC, Holroyd BR, Rowe BH. ED management of cellulitis: a review of five urban centers. Am J Emerg Med 2001;19:535-40.
16. Cephalosporins. In: McEvoy GK, ed. American Society of Health-System Pharmacists drug information. 45th ed. Bethesda, MD: American Society of Health-System Pharmacists American Hospital Formulary Service, 2003:125-223.
17. Uricosuric agents. In: McEvoy GK, ed. American Society of Health-System Pharmacists drug information. 45th ed. Bethesda, MD: American Society of Health-System Pharmacists American Hospital Formulary Service, 2003:2557-62.
18. Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 1981;6:135-51.
19. Tjandramaga TB, Cucinell SA, Israili ZH, Perel JM, Dayton PG, Yu TF, et al. Observations on the disposition of probenecid in patients receiving allopurinol. Pharmacology 1972;8:259-72.
20. Brown GR. Cephalosporin-probenecid drug interactions. Clin Pharmacokinet 1993;24:289-300.
21. Zed PJ, Harder C, Harrison DW, Purssell RA. Efficacy of once daily cefazolin/probenecid for the outpatient management of skin and soft tissue infections (abstract). Can J Emerg Med 2001;3:139-40.
22. Kirby WMM, Regamey C. Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis 1973;128(suppl):S341-5.
23. Karney WW, Turck M, Holmes KK. Cefazolin in the treatment of gonorrhea. J Infect Dis 1973;128(suppl):S399-403.
24. Duncan WC. Treatment of gonorrhea with cefazolin plus probenecid. J Infect Dis 1974;130:398-401.
25. Rein MF, Westervelt FB, Sande MA. Pharmacodynamics of cefazolin in the presence of normal and impaired renal function. Antimicrob Agents Chemother 1973;4:366-71.
26. Brown G, Zemcov SJV, Clarke AM. Effect of probenecid on cefazolin serum concentrations. J Antimicrob Chemother 1993;31:1009-11.
27. Spina SP, Dillon EC Jr. Effect of chronic probenecid therapy on cefazolin serum concentrations. Ann Pharmacother 2003;37:621-4. DOI 10.1345/ aph.1C347
28. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999;115(3 suppl):19S-23S.
29. Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC. What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 2001;21 (11 pt 2):302S-18S.
30. Rodvold KA. Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside. Pharmacotherapy 2001;21(11 pt 2): 319S-30S.
31. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
32. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996;25:213-7.
33. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
34. Andes D, Craig WA. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect Dis Clin North Am 1998;12:849-60.
35. Karchmer AW. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000:274-91.
36. Stoeckel K, Trueb V, Dubach UC, McNamara PJ. Effect of probenecid on the elimination and protein binding of ceftriaxone. Eur J Clin Pharmacol 1988;34:151-6.
37. Performance standards for antimicrobial susceptibility testing; twelfth informational supplement. NCCLS document M100-S12. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.